Financial Results

News & Events

Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors

May 29, 2019

Daix (France), May 29, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the appointment of Nawal Ouzren and Heinz Maeusli as members of its Board of Directors following the Company’s Ordinary and Extraordinary Shareholders’ General Meeting on May 27, 2019.

As such, Mrs Nawal Ouzren and Mr Heinz Maeusli will follow Mr Chris Newton, Mrs Nanna Lüneborg and Mr Jean-Louis Junien whose terms of office as Directors have officially ended. Mr Jean-Louis Junien will now focus on the creation of Inventiva’s Scientific Advisory Board. In addition, during the Annual General Meeting, the mandates of Frédéric Cren, Pierre Broqua, CELL + and Pienter-Jan BVBA have been renewed.

Frédéric Cren, Chairman, CEO and Cofounder of Inventiva, said: “We are delighted to welcome Nawal and Heinz as new members of Inventiva’s Board of Directors. Their solid track records in the pharmaceutical industry and their complementary profiles will be a great addition to Inventiva’s Board. Their experiences in listed companies of various sizes paired with a strong knowledge of the European and US financial markets will be very valuable for Inventiva’s future development. On behalf of the whole Board, I would like to extend my thanks to Chris, Nanna and Jean-Louis for their continued dedication and contribution to Inventiva’s development in the past few years.

The results of the vote related to the composition of the Board of Directors as well as those related to the remaining resolutions are available on Inventiva’s website: http://inventivapharma.com/investors/shareholder-meetings/.

About Nawal Ouzren

With more than 15 years of experience in operational and strategic management within the pharmaceutical industry, Mrs Ouzren has been Chief Executive Officer and Director of Sensorion since 2017. She started her career at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilars business unit. In 2014, Mrs Ouzren became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she headed up the Global Genetic Diseases Franchise at Shire, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.

Nawal Ouzren holds a Master’s degree in Chemical Engineering from the Technical University of Berlin, Germany, and a Master of Science in Chemical Engineering from the Université de Technologie de Compiègne, France.

About Heinz Maeusli

Chief Financial Officer of Advanced Accelerator Applications (AAA) from 2003 to 2018, Heinz Maeusli has been instrumental in growing this company into a global leader in its sector. As such, he has driven the listing of AAA on the Nasdaq stock exchange in November 2015 and contributed to AAA’s sale to Novartis in January 2018. Throughout his career, he has developed an expertise in the operational, organizational, financial and cultural complexities of growing and integrating international companies.

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick

Aude Hillion/ Yannick Tetzlaff
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.